New antibody shot shows promise for Tough-to-Treat arthritis
NCT ID NCT06590090
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial tests whether adding a lab-made antibody called natrunix to standard methotrexate treatment helps people with moderate to severe rheumatoid arthritis who haven't improved enough on methotrexate alone. About 108 participants will receive weekly shots of either natrunix or a placebo for 14 weeks, followed by an open-label extension where everyone can get natrunix. The main goal is to see if more people achieve at least a 20% improvement in arthritis symptoms.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Natrunix (a lab-made antibody similar to a natural human antibody that blocks IL-1a), given as a shot under the skin, plus methotrexate
What this could lead to
If it works, this could offer a new treatment option for people with rheumatoid arthritis who do not respond well to methotrexate alone.
What could go wrong
This is an early Phase 2 trial with only 108 people, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••